171 related articles for article (PubMed ID: 30348070)
1. Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy.
Gharaibeh EZ; Telfah M; Powers BC; Salacz ME
J Oncol Pharm Pract; 2019 Oct; 25(7):1784-1786. PubMed ID: 30348070
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy.
Lentz KL; Clark SM; Ayarza M; Liu B; Morgan KP; Wind LS; Hairston A
J Oncol Pharm Pract; 2020 Mar; 26(2):406-412. PubMed ID: 31288633
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide neurotoxicty in a young female with a remarkable response to thiamine.
Imtiaz S; Muzaffar N
J Pak Med Assoc; 2010 Oct; 60(10):867-9. PubMed ID: 21381624
[TBL] [Abstract][Full Text] [Related]
4. The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report.
Yeo KK; HaDuong JH
J Pediatr Hematol Oncol; 2016 Aug; 38(6):489-90. PubMed ID: 26907647
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
Aeschlimann C; Küpfer A; Schefer H; Cerny T
Drug Metab Dispos; 1998 Sep; 26(9):883-90. PubMed ID: 9733667
[TBL] [Abstract][Full Text] [Related]
7. [Ifosfamide induced encephalopathy: 15 observations].
Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
[TBL] [Abstract][Full Text] [Related]
8. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy.
Küpfer A; Aeschlimann C; Cerny T
Eur J Clin Pharmacol; 1996; 50(4):249-52. PubMed ID: 8803513
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case.
Müngen E; Yaman Bajin İ; Öz S; Günbey C; Anlar B; Aydin B
J Pediatr Hematol Oncol; 2022 Oct; 44(7):402-404. PubMed ID: 35536996
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide induced encephalopathy in a child with osteosarcoma.
Sarbay H; Demir ÜF; Yılmaz G; Atay AA; Malbora B
J Oncol Pharm Pract; 2021 Jul; 27(5):1302-1306. PubMed ID: 33023384
[TBL] [Abstract][Full Text] [Related]
11. Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?
Abahssain H; Moukafih B; Essangri H; Mrabti H; Meddah B; Guessous F; Fadhil FZ; Souadka A; Errihani H
J Oncol Pharm Pract; 2021 Jan; 27(1):143-149. PubMed ID: 33153383
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.
Cherry MA; Bhardwaj H; Hopps S; Srour S; Pant S
J Oncol Pharm Pract; 2013 Sep; 19(3):261-4. PubMed ID: 23135805
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity.
Richards A; Marshall H; McQuary A
J Oncol Pharm Pract; 2011 Dec; 17(4):372-80. PubMed ID: 20861178
[TBL] [Abstract][Full Text] [Related]
14. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken JB
Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Liu YL; Tsai SH; Chang FW; Yu MH
Taiwan J Obstet Gynecol; 2010 Mar; 49(1):77-80. PubMed ID: 20466298
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer.
Ataseven E; Göktepe ŞÖ; Kantar M
J Oncol Pharm Pract; 2021 Dec; 27(8):2018-2022. PubMed ID: 33779369
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.
Küpfer A; Aeschlimann C; Wermuth B; Cerny T
Lancet; 1994 Mar; 343(8900):763-4. PubMed ID: 7510815
[TBL] [Abstract][Full Text] [Related]
19. [Malignant lymphoma complicated with posterior reversible encephalopathy].
Thomsen RH; Zakarian K; Hansen PB
Ugeskr Laeger; 2015 Sep; 177(37):V03150236. PubMed ID: 26376238
[TBL] [Abstract][Full Text] [Related]
20. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
